Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine for prevention of perioperative pulmonary complications after VATS in high-risk NSCLC
ChiCTR2400090022Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of penehyclidine in anoxemia and Airways Infection (3 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Arterial oxygen saturation and Postoperative inflammatory pulmonary lesions. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
anoxemiaAirways Infection
Beyond the preview
Go deeper on ChiCTR2400090022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090022.